RCM
CERE

RA Capital Management’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

RA Capital Management’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,200,000
Closed -$56.4M – 106
2021
Q2 		$56.4M Hold
2,200,000
– – 0.9% 34
2021
Q1 		$30.2M Hold
2,200,000
– – 0.46% 50
2020
Q4 		$36.5M Buy
+2,200,000
New +$28.6M 0.51% 48

Other funds holding CERE

BCI
Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

RA Capital Management's CERE Position: Q3 2021 in Review

RA Capital Management sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2021, closing a stake of 2,200,000 shares — an estimated $56.4M sold.

RA Capital Management first reported a position in CERE in Q4 2020 and held it in 3 quarters. The position peaked at $56.4M in Q2 2021. 94 funds tracked by Wall St. Rank hold CERE as of Q3 2021.

  • RA Capital Management reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • RA Capital Management sold 2,200,000 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2021, an estimated $56.4M.
  • RA Capital Management first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2020 and held it in 3 quarters.
  • RA Capital Management's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $56.4M in Q2 2021.
  • 94 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2021.

Based on RA Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.